Solventum, which spun off from 3M in 2024, is divesting a division with $1.4 billion in annual sales. While HIS is a billion-dollar unit, as a software provider to health care systems, it is different than Solventum's other businesses. Solventum sharpened that portfolio already last year by selling its purification business to Thermo Fisher Scientific for $4 billion. Hanson told analysts that the HIS business had been operating more or less independently since then, making a separation relatively easy. Total reported sales for the quarter, including the divestiture of the purification business, increased 2.2% to $2.2 billion.